Exagen Inc. (NASDAQ:XGN) Q3 2023 Earnings Conference Call November 13, 2023 4:30 PM ET
Company Participants
Ryan Douglas - IR
John Aballi - President and CEO
Kamal Adawi - CFO
Conference Call Participants
Kyle Mikson - Canaccord Genuity
Mark Massaro - BTIG
Dan Brennan - TD Cowen
Andrew Brackmann - William Blair
Operator
Greetings, and welcome to the Exagen Inc. Third Quarter 2023 Earnings Conference Call. [Operator Instructions] And as a reminder, this conference is being recorded.
And it is now my pleasure to introduce to you, Ryan Douglas with Investor Relations. Thank you, Ryan. Please go ahead.
Ryan Douglas
Good afternoon and thank you for joining us. Earlier today, Exagen Inc. released financial results for the quarter ended September 30, 2023. The release is currently available on the company's website at www.exagen.com. John Aballi, the President and Chief Executive Officer; and Kamal Adawi, Chief Financial Officer, will host this afternoon's call.
Before we get started, I'd like to remind everyone that management will be making statements during this call that include forward-looking statements within the meaning of federal securities laws, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Any statements contained in this call that are not statements of historical facts should be deemed to be forward-looking statements. All forward-looking statements, including, without limitation, statements regarding our business strategy and future financial and operating performance, including guidance for the quarter, potential profitability. Our current and future product offerings and reimbursement and coverage are based upon current estimates and various assumptions.
These statements involve material risks and uncertainties that could cause actual results to differ materially from those anticipated or implied by these forward-looking statements. Accordingly, you should not place undue reliance on these statements. For a list and all description of risks and uncertainties associated with our business, please see our filings with the Securities and Exchange Commission, including our Form 10-K for the year ended December 31, 2022, and any subsequent filings.
In addition, some of the information discussed today includes non-GAAP financial measures such as adjusted EBITDA that have not been calculated in accordance with generally accepted accounting principles in the United States or GAAP. These non-GAAP items should be used in addition to and not as a substitute for any GAAP results. We believe these metrics provide useful supplemental information in assessing our revenue and operating performance. Reconciliations of these non-GAAP financial measures to the most directly comparable GAAP financial measures are presented in the tables at the end of our earnings release issued earlier today, which has been posted on the Investor Relations page of the company's website.